

ASTRAZENECA PLC

Non-statutory Financial Statements

Registered number 2723534

31 March 2012

MONDAY



A18XX1UW

A24

14/05/2012

#126

COMPANIES HOUSE

PROFIT AND LOSS ACCOUNT
for the period/year ended

	Notes	31 March 2012 \$m	31 December 2011 \$m
Turnover		-	-
Operating costs		(2)	(38)
Operating loss		(2)	(38)
Income from shares in subsidiary undertakings	2	14,500	3,000
Profit on ordinary activities before interest		14,498	2,962
Net interest	3	2	(1)
Profit on ordinary activities before taxation		14,500	2,961
Taxation		-	-
Profit for the period/year		14,500	2,961

STATEMENT OF TOTAL RECOGNISED GAINS AND LOSSES
for the period/year ended

	31 March 2012 \$m	31 December 2011 \$m
Net profit for the period/year	14,500	2,961
Amortisation of loss on cash flow hedge	-	2
Total recognised gains for the period/year	14,500	2,963

BALANCE SHEET

	Notes	31 March 2012 \$m	31 December 2011 \$m
Fixed assets			
Fixed asset investments	5	23,494	23,421
Current assets			
Debtors - other		1	1
Debtors - amounts owed by Group undertakings		9,854	1,937
		9,855	1,938
Creditors: Amounts falling due within one year			
Non-trade creditors	6	(154)	(3,217)
Interest bearing loans and borrowings	7	(1,749)	(1,749)
		(1,903)	(4,966)
Net current assets/(liabilities)		7,952	(3,028)
Total assets less current liabilities		31,446	20,393
Creditors: Amounts falling due after more than one year			
Amounts owed to Group undertakings	7	(283)	(283)
Interest bearing loans and borrowings	7	(6,764)	(6,714)
Net assets		24,399	13,396
Capital and reserves			
Called-up share capital	8	318	323
Share premium account	9	3,220	3,078
Capital redemption reserve	9	145	139
Other reserves	9	2,893	2,983
Profit and loss account	9	17,823	6,873
Shareholders' funds	10	24,399	13,396

\$m means millions of US dollars

The Financial Statements on pages 1 to 7 were approved by the Board of Directors on 25 April 2012 and were signed on its behalf by



David R Brennan
Director



Simon Lowth
Director

NOTES TO THE FINANCIAL STATEMENTS

1 Basis of presentation of financial information

These AstraZeneca PLC non-statutory financial statements are presented in accordance with the accounting policies set out in the AstraZeneca Annual Report and Form 20-F Information 2011. The auditors' report on those accounts was unqualified and did not contain any statement under Section 498 of the Companies Act 2006.

These financial statements do not constitute statutory accounts of the Company within the meaning of Section 435 of the Companies Act 2006.

2 Income from shares in subsidiary undertakings

	31 March 2012 \$m	31 December 2011 \$m
Dividends received from subsidiary undertakings	14,500	3,000

3 Net interest

	31 March 2012 \$m	31 December 2011 \$m
Interest payable and similar charges		
Payable to subsidiary undertakings	(5)	(20)
External interest payable	(126)	(506)
	(131)	(526)
Interest receivable and similar income		
Receivable from subsidiary undertakings	131	523
Net exchange and hedge gains	2	2
	133	525
Net interest	2	(1)

NOTES TO THE FINANCIAL STATEMENTS (continued)

4 Dividends to shareholders

	31 March 2012 per share	31 December 2011 per share	31 March 2012 \$m	31 December 2011 \$m
2 nd interim	\$1 95	\$1 85	2,495	2,594
1 st interim	-	\$0 85	-	1,158
	\$1 95	\$2 70	2,495	3,752

5 Fixed asset investments

	Investments in subsidiaries		
	Shares \$m	Loans \$m	Total \$m
Cost and net book value at 1 January 2012	16,427	6,994	23,421
Capital contribution – share awards	23	-	23
Exchange	-	49	49
Amortisation	-	1	1
Cost and net book value at 31 March 2012	16,450	7,044	23,494

6 Non-trade creditors

	31 March 2012 \$m	31 December 2011 \$m
Amounts due within one year		
Short-term borrowings (unsecured)	24	14
Other creditors	56	170
Amounts owed to Group undertakings	74	3,033
	154	3,217

NOTES TO THE FINANCIAL STATEMENTS (continued)

7 Loans

	Repayment dates	31 March 2012 \$m	31 December 2011 \$m
Amounts due within one year			
Interest bearing loans and borrowings (unsecured)			
US dollars			
5 4% Callable bond	2012	1,749	1,749
Amounts due after more than one year			
Amounts owed to subsidiaries (unsecured)			
US dollars			
7 2% Loan	2023	283	283
Interest-bearing loans and borrowings (unsecured)			
US dollars			
5 4% Callable bond	2014	749	749
5 9% Callable bond	2017	1,745	1,744
6 45% Callable bond	2037	2,716	2,716
Euros			
5 125% Non-callable bond	2015	999	969
Pounds sterling			
5 75% Non-callable bond	2031	555	536
		6,764	6,714

8 Share capital

	Allotted, called-up and fully paid	
	31 March 2012 \$m	31 December 2011 \$m
Issued Ordinary Shares (\$0.25 each)	318	323
Redeemable Preference Shares (£1 each - £50,000)	-	-
	318	323

At 31 March 2012, 1,273,930,953 Ordinary Shares were in issue

The movements in share capital during the period can be summarised as follows

	No. of shares (million)	\$m
At 1 January 2012	1,292	323
Issues of shares	4	1
Repurchase of shares	(22)	(6)
At 31 March 2012	1,274	318

NOTES TO THE FINANCIAL STATEMENTS (continued)

9 Reserves

	Share premium account \$m	Capital redemption reserve \$m	Other reserves \$m	Profit and loss account \$m	31 Mar 2012 Total \$m	31 Dec 2011 Total \$m
At beginning of year	3,078	139	2,983	6,873	13,073	19,476
Profit for the period/year	-	-	-	14,500	14,500	2,961
Dividends	-	-	-	(2,495)	(2,495)	(3,752)
Amortisation of loss on cash flow hedge	-	-	-	-	-	2
Share-based payments	-	-	(90)	-	(90)	(37)
Share repurchases	-	6	-	(1,055)	(1,049)	(5,983)
Issues of shares	142	-	-	-	142	406
At end of period/year	3,220	145	2,893	17,823	24,081	13,073
Distributable reserves at end of period/year	-	-	1,841	17,823	19,664	8,714

At 31 March 2012, \$17,823m (31 December 2011 \$6,873m) of the profit and loss account reserve was available for distribution. Included in other reserves is a special reserve of \$157m, arising on the redenomination of share capital in 1999.

Included within other reserves at 31 March 2012 is \$1,052m (31 December 2011 \$1,142m) in respect of cumulative share-based payment awards. These amounts are not available for distribution.

10 Reconciliation of movements in shareholders' funds

	31 March 2012 \$m	31 December 2011 \$m
At beginning of year	13,396	19,828
Net profit for the period/year	14,500	2,961
Dividends	(2,495)	(3,752)
Amortisation of loss on cash flow hedge	-	2
Share-based payments	(90)	(37)
Issues of AstraZeneca PLC Ordinary Shares	143	409
Repurchase of AstraZeneca PLC Ordinary Shares	(1,055)	(6,015)
Net increase/(decrease) in shareholders' funds	11,003	(6,432)
Shareholders' funds at end of period/year	24,399	13,396

Details of dividends paid and payable to shareholders are given in Note 4.

NOTES TO THE FINANCIAL STATEMENTS (continued)

11 Litigation and environmental liabilities

In addition to those matters disclosed below, there are other cases where the Company is named as a party to legal proceedings. These include the *Seroquel* product liability litigation, the *Seroquel* Attorney General commercial litigation, the *Nexium* product liability litigation, and the *Symbicort* freedom to operate lawsuit (Accuhale LLC v AstraZeneca) each of which are described more fully in Note 25 to the Group Financial Statements which can be found in the AstraZeneca Annual Report and Form 20-F Information 2011.

Foreign Corrupt Practices Act

In connection with an investigation into Foreign Corrupt Practices Act issues in the pharmaceutical industry, AstraZeneca has received inquiries from the US Department of Justice and the SEC regarding, among other things, sales practices, internal controls, certain distributors and interactions with healthcare providers in several countries. AstraZeneca is cooperating with these inquiries. AstraZeneca is investigating indications of inappropriate conduct in certain countries, including China.

European Commission investigation

The European Commission has closed its investigation into alleged practices regarding *Nexium* and alleged breaches of EU competition laws.

European Commission case

AstraZeneca is awaiting a ruling on the cross-appeals from the General Court of the EU's judgment regarding the European Commission's 2005 Decision fining AstraZeneca €60m (reduced to €52.5m by the General Court) for abuse of a dominant position regarding omeprazole. An oral hearing took place on 12 January 2012.

Dutch Competition Authority investigation

The Dutch National Competition Authority (NMa) investigation into alleged practices regarding *Nexium* and alleged breaches of both Dutch and EU competition laws is ongoing. In December 2011, the investigation team issued a report alleging foreclosure of generic versions of certain Proton Pump Inhibitors. The file has now been passed to the Legal Department of the NMa.